Prashant V. Bommi
YOU?
Author Swipe
View article: TMIC-14. A novel IDO1 PROTAC decreases immunosuppressive extracellular IDO1 levels
TMIC-14. A novel IDO1 PROTAC decreases immunosuppressive extracellular IDO1 levels Open
BACKGROUND Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme expressed in >90% of patient-resected glioblastoma (GBM). IDO1 expression is inversely correlated with GBM patient survival. Extracellular IDO1 contributes t…
View article: Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205 Open
This phase I trial evaluated the IDO1 enzyme inhibitor, BMS-986205, with radiation (RT) and nivolumab treatment in newly diagnosed patients with GBM IDHwt. Cohort A received RT + nivolumab with escalating BMS-986205 doses in MGMT unmethyla…
View article: Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC) Open
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and nonenzymatic functions. Drugs targeting IDO1 enzyme activity have failed to improve the overall su…
View article: Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC) Open
Indoleamine 2,3-dioxygenase 1 (IDO1) is a potently immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and non-enzymatic functions. Pharmacological therapies targeting IDO1 enzyme activity have gen…
View article: CNSC-38. INFLUENCE OF AGE, IMMUNOREGULATORY IDO, AND IMMUNOTHERAPY ON THE MICROBIOME IN MICE WITH AN EXPERIMENTAL BRAIN TUMOR
CNSC-38. INFLUENCE OF AGE, IMMUNOREGULATORY IDO, AND IMMUNOTHERAPY ON THE MICROBIOME IN MICE WITH AN EXPERIMENTAL BRAIN TUMOR Open
OBJECTIVE This study aimed to determine how IDO and subject age impact the gut microbiome and microbial metabolites during immunotherapy for glioblastoma (GBM). METHODS Serum and colon contents were collected from young 16-20- or older adu…
View article: CNSC-47. SENOLYTICS ERADICATE SENESCENT MICROGLIA IN THE BRAIN PARENCHYMA AND IMPROVE SURVIVAL IN OLDER ADULT MICE WITH GLIOBLASTOMA
CNSC-47. SENOLYTICS ERADICATE SENESCENT MICROGLIA IN THE BRAIN PARENCHYMA AND IMPROVE SURVIVAL IN OLDER ADULT MICE WITH GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a poor median survival rate. Despite the aggressive standard of care treatment combining surgical resection, chemo-, and radio-therapy…
View article: Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma
Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma Open
Age-dependent novel associations between clinical symptoms and medications prescribed for co-morbid conditions were demonstrated in patients with GBM. The results of the current work support future mechanistic studies that investigate the …
View article: Data from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Data from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Purpose:Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient survival, the predominant …
View article: Supplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Supplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Supplementary Figures
View article: Data from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Data from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Purpose:Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient survival, the predominant …
View article: Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Supplementary Tables
View article: Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Supplementary Tables
View article: Supplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Supplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Supplementary Figures
View article: IMMU-27. NON-TUMOR CELL IDO1 NON-ENZYMATICALLY DECREASES RT + PD-1 MAB TREATMENT EFFICACY IN OLDER ADULTS WITH GLIOBLASTOMA
IMMU-27. NON-TUMOR CELL IDO1 NON-ENZYMATICALLY DECREASES RT + PD-1 MAB TREATMENT EFFICACY IN OLDER ADULTS WITH GLIOBLASTOMA Open
Checkmate 498 is a large, randomized, phase 3 clinical trial that demonstrated an improved hazard ratio for younger but not older adults with MGMT unmethylated GBM treated with RT + PD-1 mAb. In an effort to better understand the biologica…
View article: CSIG-33. A 2ND GENERATION IDO1 PROTEIN DEGRADER TO OVERCOME NON-ENZYME-MEDIATED IDO1-DEPENDENT IMMUNE SUPPRESSION FOR GLIOBLASTOMA
CSIG-33. A 2ND GENERATION IDO1 PROTEIN DEGRADER TO OVERCOME NON-ENZYME-MEDIATED IDO1-DEPENDENT IMMUNE SUPPRESSION FOR GLIOBLASTOMA Open
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into the downstream catabolite, kynurenine. IDO1 is expressed in >90% of patient-resected gli…
View article: Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence Open
Purpose: Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient survival, the predominant…
View article: Supplementary Figures from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Supplementary Figures from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Supplementary Figures S1-S5
View article: Data from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Data from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome, which results in the development of hundreds of adenomatous polyps carpeting the gastrointestinal tract. NSAIDs have reduced polyp burden in patients with FAP…
View article: Supplementary Figures from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Supplementary Figures from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Supplementary Figures S1-S5
View article: Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis Open
Bmi1 is a polycomb group proto-oncogene that has been implicated in multiple tumor types. However, its role in hepatocellular carcinoma (HCC) development has not been well studied. In this article, we report that Bmi1 is overexpressed in h…
View article: Data from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Data from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome, which results in the development of hundreds of adenomatous polyps carpeting the gastrointestinal tract. NSAIDs have reduced polyp burden in patients with FAP…
View article: Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis Open
Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
View article: Supplementary Tables from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Supplementary Tables from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Supplementary Tables S1-S4
View article: Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis Open
Bmi1 is a polycomb group proto-oncogene that has been implicated in multiple tumor types. However, its role in hepatocellular carcinoma (HCC) development has not been well studied. In this article, we report that Bmi1 is overexpressed in h…
View article: Supplementary Tables from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis
Supplementary Tables from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis Open
Supplementary Tables S1-S4
View article: Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis Open
Supplementary Data from Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
View article: Supplementary Tables S1-S9 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Supplementary Tables S1-S9 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells Open
Supplementary Tables S1-S9
View article: Data from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Data from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells Open
Lynch syndrome is the most common cause of hereditary colorectal cancer and is secondary to germline alterations in one of four DNA mismatch repair (MMR) genes. Here we aimed to provide novel insights into the initiation of MMR-deficient (…
View article: Supplementary Tables S1-S9 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Supplementary Tables S1-S9 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells Open
Supplementary Tables S1-S9
View article: Supplementary Figures S1-S6 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Supplementary Figures S1-S6 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells Open
Supplementary Figures S1-S6